HDAC-an important target for improving tumor radiotherapy resistance

Area of Science:

• Oncology
• Epigenetics
• Cancer Biology

Background:

• Radiotherapy is a cornerstone of cancer treatment, but resistance remains a significant clinical challenge.
• Mechanisms of radiotherapy resistance involve DNA repair, cell cycle, and epigenetic modifications.
• Histone deacetylases (HDACs) are key epigenetic regulators implicated in various cancer processes.

Purpose of the Study:

• To systematically elucidate the mechanisms by which HDACs promote tumor radiotherapy resistance.
• To explore the clinical application prospects of HDAC inhibitors in overcoming radiotherapy resistance.
• To provide a reference for HDAC-related drug development and future research directions.

Main Methods:

• Review and synthesis of existing literature on HDACs and radiotherapy resistance.
• Analysis of in vivo and in vitro studies detailing HDAC involvement in resistance mechanisms.
• Examination of the role of epigenetic modifications in cellular responses to radiation.

Main Results:

• HDACs promote radiotherapy resistance through diverse mechanisms including DNA damage repair, cell cycle regulation, and apoptosis modulation.
• Epigenetic alterations regulated by HDACs are critical in the development of treatment resistance.
• HDAC inhibitors show promise in preclinical models for enhancing radiotherapy efficacy.

Conclusions:

• HDACs play a crucial role in promoting tumor radiotherapy resistance via epigenetic regulation.
• HDAC inhibitors represent a promising therapeutic strategy to overcome radiotherapy resistance.
• Further research into HDACs and their inhibitors is warranted to improve cancer treatment outcomes.